Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Buzz on the Bullboards: Which stocks are turning inertia into momentum?

Markets have stumbled this week, especially tech indices as rising bond yields in the U.S. have had their way with the sector, which is sensitive to higher interest rates. One of the big updates of late, Datametrex AI Ltd. (TSXV:DM) brought investors up to spe...
Jonathon Brown | March 30, 2023 |

Fed Goes All In - As In All In, and Stocks Like It

On the heels of the Fed’s unlimited QE promise, the S&P 500 sprang to life finally. All the gains though were given up in less than three hours. As the futures keep climbing overnight, does it herald a turnaround? Let’s start our analysis wi...
Monica Kingsley | March 24, 2020 |

Buzz on the Bullboards: When will the bear awaken?

2023 has started off with a bang for investors, as many sectors continue to adjust to rising inflation. It has been an up-and-down week for Canadian markets so far, but there seems to be an upbeat sentiment from markets across the globe. Many expect the Federal Reserv...
Jonathon Brown | January 12, 2023 |

Theralase is raising up to $5.3M to complete bladder cancer study

Theralase Technologies is announcing a brokered financing raise for up to C$5.3 million Proceeds of the financing will be used to further the Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study Ruvidar is designed to destroy solid core tum...
Coreena Robertson | November 6, 2023 |

The coming supply crunch

As I write and you read, the world economy is getting pummeled, one blow after another, by demand destruction, as economies grind to a screeching halt due to unprecedented restrictions on economic and social activity owing to the relentless spread of the covid-19 coronavirus...
Richard (Rick) Mills | April 7, 2020 |

Mickey Fulp: 'Never Let a Good Crisis Go to Waste'

Maurice: Today we will find out if we are at risk of losing our liberty to the coronavirus, along with buying opportunities for your investment portfolio. Joining us for a conversation is Mickey Fulp, the world-renowned Mercenary Geologist . Absolute delight to speak ...
Streetwise Reports | March 31, 2020 |

Central Bank Hypnosis

One look at the chart of the U.S. financial markets against the backdrop of economic paralysis and suffering, and one is immediately filled with a myriad of emotions. Sympathy for those that have been afflicted by the most recent pandemic; fear for the families whose prim...
Streetwise Reports | June 2, 2020 |

Buzz on the Bullboards: Are We Headed for a Major Market Correction?

(Image via Datametrex AI Limited.) Datametrex AI Ltd. ( TSX-V: DM , Forum ) announced this week that achieved the highest net income and revenue in its history. A technology-focused company with exposure to Artificial Intelligence and Machine Learning, Datametr...
Stockhouse Editorial | August 18, 2021 |

Global Central Banks Move To Keep The Party Rolling Onward – Part I

The recent news that the US Fed, China and many of the global central banks are continuing to make efforts to lower rates and spark further consumer spending and economic activity is reminiscent of the late 2010~2013 global economic recovery efforts. This was a time when the e...
Chris Vermeulen | August 14, 2019 |

ChemoCentryx Shares Spike 300% on Phase 3 ANCA Vasculitis Trial Results

Shares of ChemoCentryx Inc. opened greater than 330% higher today after the firm reported positive topline data from its pivotal Phase 3 ADVOCATE trial of Avacopan in treatment of ANCA-associated vasculitis. After the U.S. markets closed yesterday, ChemoCentryx Inc. ...
Streetwise Reports | November 27, 2019 |
1 2 3 4 5 6 7